What is Eagle Genomics?
Eagle Genomics operates at the critical intersection of biology, data science, and bioinformatics. Its flagship platform, e[datascientist], serves as a transformative tool for global enterprises, enabling the rapid exploitation of multi-dimensional data. By streamlining the innovation workflow—from initial hypothesis to final product claims—the company empowers organizations in the Food and Nutrition, Beauty and Personal Care, AgBio, and BioPharma sectors to bring sustainable, science-led products to market with unprecedented speed. The firm is particularly recognized for its leadership in microbiome research, having played a foundational role in shaping the UK Microbiome Strategic Roadmap.
How much funding has Eagle Genomics raised?
Eagle Genomics has raised a total of $16.3M across 6 funding rounds:
Unspecified
$918K
Unspecified
$661K
Unspecified
$1.3M
Unspecified
$1M
Unspecified
$3.5M
Unspecified
$9M
Unspecified (2013): $918K with participation from Cambridge Capital Group, Midven, and London Business Angels
Unspecified (2013): $661K led by London Business Angels and Angel CoFund
Unspecified (2016): $1.3M supported by Newable Private Investing and Angels in MedCity
Unspecified (2018): $1M featuring UK Innovation & Science Seed Fund
Unspecified (2019): $3.5M backed by UK Innovation & Science Seed Fund, Environmental Technologies Fund, and Newable Private Investing
Unspecified (2020): $9M with participation from ETF Partners LLP
Key Investors in Eagle Genomics
ETF Partners LLP
A venture capital firm focused on sustainability through innovation, supporting talented entrepreneurs with capital and deep institutional experience.
Midven
A Birmingham-based venture capital firm that provides strategic capital and hands-on mentorship to high-growth potential businesses.
Angel CoFund
A dedicated investment fund that collaborates with sector-focused angel investors to drive capital growth in promising UK-based enterprises.
What's next for Eagle Genomics?
With the infusion of recent capital, Eagle Genomics is well-positioned to deepen its market penetration and enhance its AI capabilities. The company's strategic roadmap focuses on expanding its footprint within the BioPharma and AgBio sectors, where the demand for high-throughput data analysis is surging. By fostering deeper relationships with scientific establishments and leveraging its e[datascientist] platform, the firm aims to set new industry standards for safety and sustainability. Future growth will likely center on scaling its operational infrastructure to support global enterprise clients, ensuring that the digital reinvention of science remains a core driver of next-generation product development.
See full Eagle Genomics company page
